Oncternal Therapeutics (ONCT) Insider Trading & Ownership $0.53 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Oncternal Therapeutics (NASDAQ:ONCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.20%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$92,735.84Number OfInsiders Selling(Last 12 Months)0 Get ONCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Oncternal Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ONCT Insider Buying and Selling by Quarter Oncternal Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/8/2024Robert James WillsDirectorBuy3,086$8.96$27,650.56 3/28/2024Robert James WillsDirectorBuy6,914$8.48$58,630.72 2/23/2024David F HaleDirectorBuy714$9.04$6,454.56 (Data available from 1/1/2013 forward) ONCT Insider Trading Activity - Frequently Asked Questions Who is on Oncternal Therapeutics's Insider Roster? The list of insiders at Oncternal Therapeutics includes Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent, Robert James Wills, and Salim Yazji. Learn more on insiders at ONCT. What percentage of Oncternal Therapeutics stock is owned by insiders? 11.20% of Oncternal Therapeutics stock is owned by insiders. Learn more on ONCT's insider holdings. Which Oncternal Therapeutics insiders have been buying company stock? The following insiders have purchased ONCT shares in the last 24 months: Chase C Leavitt ($4,350.00), David F Hale ($6,454.56), Gunnar F Kaufmann ($9,830.00), James B Breitmeyer ($29,000.00), Richard G Vincent ($9,000.00), Robert James Wills ($86,281.28), and Salim Yazji ($4,300.00). How much insider buying is happening at Oncternal Therapeutics? Insiders have purchased a total of 20,114 ONCT shares in the last 24 months for a total of $149,215.84 bought. Oncternal Therapeutics Key ExecutivesDr. James B. Breitmeyer M.D. (Age 70)Ph.D., President, CEO & Director Compensation: $881.36kMr. Richard G. Vincent CPA (Age 60)CFO & Treasurer Compensation: $602.84kDr. Salim Yazji M.D. (Age 55)Chief Medical Officer Compensation: $648.53kDr. Rajesh Krishnan Ph.D. (Age 51)Chief Technical & Scientific Officer Mr. Chase C. Leavitt (Age 42)General Counsel & Secretary Mr. Pablo UrbanejaSenior Vice President of Corporate DevelopmentMs. Anita WisethSenior Vice President of Human Resources More Insider Trading Tools from MarketBeat Related Companies SNGX Insider Trades ONVO Insider Trades ALZN Insider Trades FRTX Insider Trades SYRS Insider Trades SONN Insider Trades UPXI Insider Trades GTBP Insider Trades ADIL Insider Trades LIPO Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:ONCT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
